
Jeplus.in
Purchase All Medicines.Get 10% Offer

PharmaShots
Shots: Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082… The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.

PharmaShots
Shots: Ensem Therapeutics has dosed the first patients in its first-in-human P-I/II trial of ETX-929, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations, including colorectal, pancreatic, NSCLC and gynecologic cancers The open-label, multicenter dose-escalation and expansion study will assess the safety, tolerability, PK, PD and preliminary antitumor activity of ETX-929 as monotherapy… The post Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors appeared first on PharmaShots.

PharmaShots
Shots: Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics to develop, manufacture & commercialize 3 pre-IND in vivo CAR-T programs for autoimmune diseases outside Greater China Starna will receive $330M upfront & is eligible for up to $2.3B in development & commercial milestones, plus royalties on net sales; Pfizer will lead clinical… The post Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases appeared first on PharmaShots.

PharmaShots
Shots: nference has entered into a strategic collaboration with Novo Nordisk to advance research in cardiometabolic diseases incl. obesity, diabetes & CV disease The collaboration will combine Novo’s clinical trial data with nference’s AI technology & federated healthcare data network to explore treatment effectiveness, safety, disease progression & long-term outcomes, with research programs aimed at… The post nference Enters into a Strategic Collaboration with Novo to Advance Research in Cardiometabolic Disease appeared first on PharmaShots.

PharmaShots
Shots: Merck has discontinued the P-III (BELLWAVE-011) study of nemtabrutinib (MK-1026) after an external Data Monitoring Committee review suggested that its benefits may not outweigh the risks in the study Following a review of the data in its totality, Merck has also discontinued the broader BELLWAVE program, including the P-III (BELLWAVE-008 & BELLWAVE-010) studies in… The post Merck Discontinues the Clinical Development Program of Nemtabrutinib Following P-III (BELLWAVE-011) Data Review appeared first on PharmaShots.
Sponsored content

Purchase All Medicines.Get 10% Offer
News
ET Pharma
Nov 19, 2026, 12:24 AM
Mazumdar-Shaw said early-stage, research-driven and pre-revenue biotech companies should be allowed to access public markets. Without such avenues, they risk being stranded without the capital needed to scale their research and businesses.
Pharma Tech
Nov 18, 2026, 9:31 PM
<p><!-- wp:paragraph --></p>
Pharma Tech
Nov 18, 2026, 5:30 PM
Experts are looking at broader reforms and reorganization to revitalise biotech’s interest in European capital markets.
ET Pharma
Nov 18, 2026, 4:02 PM
The US giant acquired nemtabrutinib, a selective BTK inhibitor, under its $2.7 billion takeover of ArQule after paying a hefty 100 per cent premium at $20 per share for the Nasdaq-listed company.
PharmaShots
Nov 18, 2026, 2:52 PM
Shots: Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082… The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.
Pharma Tech
Nov 18, 2026, 2:50 PM
GSK’s Nelkarmi will now be in direct competition with Roche’s established ALK inhibitor Alecensa.
News
Google News
Nov 19, 2026, 1:33 AM
VNVC and the American pharmaceutical company MSD announced a plan to cooperate in vaccine production at the VNVC factory, worth nearly 3 trillion VND.  Vietnam.vn
Google News
Nov 19, 2026, 1:30 AM
India and Italy Seek Stronger Collaboration in Pharma and Technology  Asianet Newsable
Google News
Nov 18, 2026, 11:16 PM
US FDA approves Regeneron's drug for generalized myasthenia gravis  Reuters
Google News
Nov 18, 2026, 11:00 PM
White House Withdraws FDA Nomination For Dr. Heidi Overton’s | PharmExec  Pharmaceutical Executive
Google News
Nov 18, 2026, 10:43 PM
Teva Pharmaceutical Industries Chief Medical Officer Eric Hughes to Depart  marketscreener.com
Google News
Nov 18, 2026, 10:38 PM
Form 8K TEVA PHARMACEUTICAL INDUSTRIES LIMITED For: 18 November By Investing.com  Investing.com Canada
Google News
Nov 18, 2026, 10:37 PM
What China’s Gene-Editing Deaths Reveal About Its Biotech Industry  Noema Magazine
Google News
Nov 18, 2026, 10:37 PM
The FDA needs stable leadership | Opinion  The Detroit News
Google News
Nov 18, 2026, 10:30 PM
Form 8K TEVA PHARMACEUTICAL INDUSTRIES LIMITED For: 18 November By Investing.com  Investing.com India
Sponsored placement

Purchase All Medicines.Get 10% Offer